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Inflammation can be protective or pathogenic depending on context and timeframe. 
Acute inflammation, including the accumulation of CD4 T cells, accompanies protective 
immune responses to pathogens, but the presence of activated CD4 T cells at sites 
of inflammation is associated with chronic inflammatory disease. While significant 
progress has been made in understanding the migration of CD4 T cells into inflamed 
sites, the signals that lead to their persistence are poorly characterized. Using a murine 
ear model of acute inflammation and intravital two-photon imaging, we have dissected 
the signals that mediate CD4 T cell persistence. We report the unexpected finding that 
the bioactive lipid, sphingosine-1-phosphate (S1P), is both necessary and sufficient 
for the persistence of activated CD4 T cells at peripheral tissues in acute inflammation. 
S1P mediated the enhanced motility of CD4 T cells at inflamed tissues but did not 
affect their migration to the downstream draining lymph node. We found that sphin-
gosine kinase-1, which regulates S1P production is increased at inflamed sites in mice 
and in patients with the chronic inflammatory disease, rheumatoid arthritis. Together, 
these data suggest that S1P, or its regulators, may be key targets to promote or disrupt 
accumulation of CD4 T cells at inflamed tissues.
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inTrODUcTiOn
The traffic of T cells through lymphoid organs, blood, and inflamed tissues is a highly regulated 
process. This ensures that each unique T cell surveys antigen presented by dendritic cells (DCs) 
in all lymphoid organs and that activated T cells migrate to sites of infection to mediate pathogen 
control. While the migration of T cells to sites of infection is protective, their sustained recruitment 
or retention can lead to chronic inflammation.
Recognition of cognate antigen by T cells in lymphoid organs leads to their arrest. Once fully 
activated, T cells exit lymph nodes (LNs), a process regulated in part by the signaling sphingolipid, 
sphingosine-1-phosphate (S1P) (1). Activated T cells then migrate to inflamed tissues under the 
control of various signals including cell adhesion molecules, tissue addressins, chemokines, and S1P 
(2, 3). While these processes have been extensively studied, the molecular signals that mediate the 
persistence of activated CD4 T cells at sites of inflammation are poorly characterized.
Many activated CD4 T cells in inflamed sites undergo apoptosis. A minority of cells will turn 
into tissue-resident memory (Trm) cells, and in some cases, inflamed sites will become chronically 
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inflamed. The sequence of molecular events leading to these 
distinct decisions is largely unknown. Expression of the 
chemokine receptor, CCR7, by T cells in peripheral tissues can 
prompt their exit into lymphatics and migration to LNs (4). 
Furthermore, growing evidence suggests that differentiation 
into resting Trm cells involves downregulation of one of the 
four receptors for S1P (S1PR1) and upregulation of CD69 (5, 6). 
These two molecules antagonize each other: S1PR1 promotes 
exit into S1P rich lymphatics while CD69 enhances retention by 
blocking S1PR1 surface expression.
By contrast, in chronic inflammation, continued activation, 
recruitment, and persistence of immune cells are accompanied 
by changes to the inflamed tissue itself. This includes increased 
vascularization and alterations to local stromal cell populations 
that can further enhance inflammation and promote activation of 
infiltrating immune cells (7–9).
Here, we investigate the molecular signals that regulate the 
residency time of activated CD4 T cells at inflamed sites. Using 
flow cytometry to quantify CD4 T cells and multiphoton laser 
scanning microscopy to analyze their movement behaviors 
in vivo, our data demonstrate an unexpected pivotal role for S1P 
in promoting the persistence of activated CD4 T cells in tissues.
Furthermore, we show that sphingosine kinase-1 (SPHK1), 
one of the enzymes responsible for the conversion of sphingosine 
into S1P, is increased at sites of acute inflammation in mice and 
in the inflamed synovium of rheumatoid arthritis (RA) patients. 
Our data suggest that increased production of S1P modulates 
CD4 T cell behavior affecting the persistence of CD4 T cells in 
sites of acute inflammation. Understanding these processes will 
have important implications for therapeutic interventions that 
seek either to increase T cell persistence at tissue sites following 
vaccination or reduce the accumulation of T  cells in chronic 
inflammation.
MaTerials anD MeThODs
animals
6-week-old male C57BL/6 mice (Envigo) were used following 
1  week of acclimatization. Transgenic mice: CD45.1+ OT-II 
T  cell receptor transgenic mice (10); OT-II mice crossed to 
hCD2-DSRed (original gifted by gifted by D. Kioussis and A. Patel, 
National Institute for Medical Research, London); CD11c-YFP 
(11); and LysMGFP (12) (originally gifted by Sussan Noursargh, 
William Harvey Research Institute) were bred in house. All mice 
were housed at the University of Glasgow and maintained under 
standard animal husbandry conditions. Experiments were cov-
ered by a Project License granted by the UK Home Office under 
the Animals (Scientific Procedures) Act of 1986 and approved by 
the University of Glasgow Ethical Review Committee.
cD4 T cell Polarization
CD4 T  cells were isolated by negative selection (STEMCELL 
Technologies) from spleens and LNs of OT-II mice and cultured 
with mitomycin c (Sigma-Aldrich) treated splenocytes in T 
helper 1 (Th1) conditions [1 µg/ml Ova Peptide323–339 (Sigma-
Aldrich), 10 µg/ml anti-IL4 (BioXcell), and 20 ng/ml IL-12 (R&D 
systems)] for 3 days in complete RPMI 1640 (Gibco) (10% FCS, 
100 µg/ml penicillin–streptomycin and 2 mM l-glutamine) at 
37°C/5% CO2.
cD4 T cell Treatments and Fluorescent 
labeling
Polarized CD4 T  cells were treated with pertussis toxin (PTX) 
(100  ng/ml) (Sigma-Aldrich), FTY720 (Sigma-Aldrich) 
(0.5 µg/ml), SEW2871 (R&D Systems) (5 µg/ml), W146 (R&D 
Systems) (5  µg/ml) or vehicle for 60  min (PTX) or 90  min in 
complete RPMI at 37°C/5% CO2. For proliferation studies, CD4 
T  cells were labeled with cell tracker blue (Thermo-Fischer 
Scientific) at 5 µM for 15 min at 37°C. After all treatments, cells 
were washed thoroughly before transfer.
intradermal lipopolysaccharide (lPs) 
administration and cD4 T cell adoptive 
Transfer
10 µg of LPS from E. coli (Sigma-Aldrich, Strain 0111:B4) was 
injected intradermally in 10  µl into the ear pinna. 1–3 ×  106 
in vitro polarized CD4 T cells were transferred intradermally into 
the same injection site. For intravital microscopy studies, 2 × 106 
CD4 T cells in 2 µl were injected intradermally at shallow depths 
to allow visualization. Ear pinnae thickness was measured using 
digital calipers (Kroeplin GmbH, model C1X018).
Tissue Preparation
Mouse ears and lymphoid organs were harvested and single cell 
suspensions prepared. Ears were digestion in 2 mg/ml Collagenase 
IV (Sigma-Aldrich), 2  mg/ml hyaluronidase (Sigma-Aldrich), 
and 100 U/ml DNase I (Invitrogen) at 37°C for 40 min at 180 
RPM in a rotating incubator. Following digestion, a single cell 
suspension was prepared with a gentlemacs dissociator (Miltenyi 
Biotec) in a gentlemacs C tube (Miltenyi Biotec). Viable cells were 
counted on a hemocytometer with dead cells excluded by trypan 
blue. LNs and spleens were disrupted into a single cell suspension 
between two pieces of 40 µm nitex.
Flow cytometry
Single cell suspensions were incubated with a fixable viability 
dye (eBioscience) for 20 min at 4°C. Samples were blocked with 
FC block (24G2 grown in house and mouse serum) for 20 min fol-
lowed by antibody staining for 20 min. Antibodies used: CD45.1 
(A20, eBioscience), CD4 (RM4-5, eBioscience), Va2 (B20.1, 
BD), MHC II (M5/114.15.2, eBioscience), CD64 (X54-5/7.1, 
BioLegend), CD8a (53-6.7, eBioscience), CD103 (M290, BD 
Horizon), Ly6G (1A8 BD), CD69 (H1.2F3, BD), S1PR1 (713412, 
R&D Systems), interferon-γ (IFN-γ) (XMG1.2, BioLegend), and 
CD44 (IM7, eBioscience). Samples were washed twice with FACS 
buffer and acquired on a Miltenyi Macsquant analyzer. Samples 
were analyzed using FlowJo (Treestar) version 9.7.5.
Multiphoton laser scanning Microscopy
A Zeiss LSM 7MP system equipped with 20×/1.0 NA water-
immersion objective lens (Zeiss UK, Cambridge, UK) and a 
tunable titanium: sapphire solid-state two-photon excitation 
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source (Chameleon Ultra II; Coherent Laser Group, Glasgow, 
UK) and optical parametric oscillator (Coherent Laser Group) 
were used. Animals were anesthetized with 10  mg/kg ketaset 
mix administered intraperitoneally. The ear was immobilized 
on a stand using veterinary grade glue and the animal’s core 
temperature maintained using a heat mat. Videos were acquired 
in 15–30 min intervals at an X–Y pixel resolution of 512 × 512 
with 1.5 µm increments in Z stack. Videos were analyzed with 
Volocity version 6 after correction for tissue drift using sec-
ond harmonic as the anchor. Individual cells were defined as 
objects and tracked in 3D. Cells were identified using intensity 
thresholding and object volume. Track plots are included to 
demonstrate the actual migration of cells relative to their point 
of origin. Displacement rate was defined as the displacement/
(time of last point on track − time of the first time point on the 
track) giving a normalized view of how far individual cells have 
traveled. Meandering index (also known as confinement ratio 
or chemotactic index) is a ratio defining track straightness. It is 
defined as the ratio of displacement of the cell to the total length 
of the track, with 0 being a highly confined cell that returns to 
its starting position, and 1 being a cell traveling in a completely 
straight line.
Patient samples
Synovial tissue specimens were obtained from RA and osteoar-
thritis (OA) patients during arthroscopic biopsy or total joint 
replacement surgeries at Glasgow Royal Infirmary (Glasgow, 
UK). All RA and OA patients fulfilled the diagnostic criteria 
for RA and OA classification respectively, and written consent 
form was obtained from all subjects. All procedures received 
Ethics Approval (West of Scotland Research Ethical Committee 
Approval: 11/S0704/7).
Mouse and human Tissue staining and 
Preparation
Mouse ears or human synovial tissues were preserved in 10% 
formalin, paraffin embedded and sectioned (10 or 5 µm, respec-
tively). Tissues were hydrated through xylene and alcohols and the 
peroxidase activity blocked. Antigens were retrieved by boiling 
in antigen retrieval buffer (Abcam). Samples were blocked with 
2.5% horse serum and an avidin/biotin kit (Vector Labs). Tissues 
were stained with rabbit polyclonal anti-SPHK1 (ab16491, 
Abcam) at 2.5  µg/ml overnight in a dehumidified chamber at 
4°C. Biotinylated anti-rabbit (1:200) (Vector Labs) in 2.5% horse 
and mouse/human serum, respectively, was added and incubated 
for 30 min at room temperature and streptavidin-PE (mouse) or 
avidin/biotin complex (human) (Vector Labs) added to the sec-
tions for 30 min. Human sections were washed and dried before 
3,3′-diaminobenzidine (Vector Labs) was added. The sections were 
developed before washing, dehydration and mounting in DPX. 
Mouse sections were mounted with DAPI+ prolong gold. Tissues 
were imaged using an Olympus BX 41 microscope attached with a 
DP 25 camera with axiovision software at 10× or 20× (human) or a 
Cell Observer SD (Zeiss) (mouse). The staining in synovial lining, 
sub-lining and vascular endothelial cell layers were graded on a 
scale of 0–4 (0 = no cells, 1 = <25%, 2 = <25–50%, 3 = < 50–75%, 
4 = 75%) by two blinded observers on two independent occasions. 
Ear sections from individual animals were imaged using a tile scan 
and analyzed using ImageJ software (NIH). Three equally sized 
areas were randomly selected per section, and the number of total 
and SPHK1+ cells manually counted.
statistical analysis
All data shown were analyzed using GraphPad Prism version 6. 
Error bars are SEM. Mann–Whitney test (two groups) or one-way 
ANOVA statistical analysis tests (more than two groups) were 
carried out with Tukey’s multiple comparison tests (ANOVA 
only) to compare the differences between groups. *Denotes p 
values of <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
resUlTs
More activated cD4 T cells are retained 
at inflamed than resting Tissue sites
The pool of T cells found at inflamed sites includes newly recruited 
cells and those that are retained, making it difficult to separate 
the signals that cause recruitment from those responsible for 
persistence. To address this, we transferred a congenic (CD45.1+) 
population of CD4 T cells directly into the ear pinnae of mice. By 
analyzing and manipulating these cells, we have developed a sys-
tem to determine the signals that regulate CD4 T cell persistence 
without the confounding factor of ongoing recruitment.
Ear pinnae were inflamed by injecting LPS intradermally into 
the tissue as it causes reproducible acute inflammation (Figure 1A). 
Peak inflammation in the ear was evident 24 h after LPS injection; 
we, therefore, focused on this time point (Figure 1B). Analysis 
of the cellular infiltrate by flow cytometry showed a large influx 
of neutrophils and CD103+ DCs but no change in the numbers 
of CD11b+ DCs, CD8α+ DCs, or macrophages (Figures 1C–F).
Activated rather than naïve CD4 T cells are found in inflamed 
peripheral tissues (13). We, therefore, transferred CD4 OT-II 
T cells differentiated into Th1 cells in vitro (14) into either resting 
(PBS injection) or LPS-inflamed ear pinnae 24 h after the initial 
LPS injection. Typically, 80%+ of the activated OT-II T  cells 
expressed IFN-γ, the signature cytokine for Th1 cells (Figure S1 
in Supplementary Material).
More OT-II T cells were recovered from inflamed compared 
with control ears 24 h after cell transfer (Figure 2A). By contrast, 
similar numbers of OT-II T cells were found in the draining LN 
(Figure 2B). Very few, if any, OT-II T cells were found in the 
contralateral cervical LNs and none were found in the spleen 
(Figure S2 in Supplementary Material). The striking difference 
in the recovery of cells in inflamed versus resting tissues 24 h 
after cell transfer, convinced us to focus on the factors that 
contributed to this early increase in CD4 T cell persistence in 
inflamed tissues.
Proliferation Does not contribute to the 
increase in number of cD4 T cells at the 
inflamed site
Increased persistence of OT-II T cells at the inflamed site could 
be due to decreased migration to the draining LN, proliferation 
FigUre 1 | Lipopolysaccharide (LPS) injection into the ear causes extensive cellular infiltrate. 24 h after the injection of PBS or LPS into ear pinnae, the response 
was examined by microscopy (a), digital calipers (B), or flow cytometry (c–F). Representative images of H&E stained sections (a) or homogenized ears (c,D) are 
shown. In panel (a), the scale bar shows 200 μm. In panel (B), an average of three individual measurements was taken for each ear pinnae. In panels (c,e), cells 
are gated on live cells, in panel (D) on live CD45+ CD11c+ cells and in panel (F) on live CD45+ CD11c+ MHCII+ cells. Data are representative of two independent 
experiments with three to five animals per group. Error bars show SEM.
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at the site, or increased survival. As we found no significant 
decrease in the numbers of CD4 T cells in the LN downstream 
of the LPS-injection site (Figure 2B), we can conclude that OT-II 
T  cells did not migrate from the inflamed tissue at a slower 
rate. Elevated numbers in the ear may have been due to either 
proliferation to increase their number and/or increased survival. 
Transfer of OT-II T cells labeled with a fluorescent cell tracker 
dye demonstrated that OT-II T cells did not proliferate in either 
resting or inflamed ears (Figure 2C). Assays to measure signs of 
apoptosis within the transferred cells proved inconclusive, most 
likely because of the extended processing required to isolate cells 
from the ears.
inflammation alters the Behavior of 
activated cD4 T cells In Vivo
In secondary lymphoid organs, interactions between CD4 T cells 
and other immune cells, especially antigen presenting DCs, can 
alter their migration patterns (15). Although specific antigen is 
not present in our in vivo model, the influx of class II positive DCs 
into inflamed ears, could lead to a reduction in cell motility that 
consequently affected their persistence. To address these ques-
tions, we imaged PBS or LPS-injected ear pinnae 4–5 h following 
transfer of fluorescently labeled activated OT-II T cells. This early 
time point enables us to identify cell behaviors that may indicate 
FigUre 2 | Lipopolysaccharide (LPS)-induced inflammation increases the persistence of activated T cells in inflamed sites. Activated OT-II T cells were transferred 
into the ear pinnae of mice injected with PBS or LPS 24 h previously. After a further 24 h, the percentages and numbers of OT-II T cells in the ears (a) or 
downstream draining lymph nodes (B) were examined by flow cytometry and their proliferation (c) assessed. In panel (c), OT-II T cells were labeled with cell tracker 
blue before transfer. In panels (a,B), cells are gated on live CD45+ cells and in panel (c) on live CD45+ cells that are CD4+ CD45.1+ (OT-II). Data are representative 
or combined from three independent experiments with ≥3 animals per group. Error bars are SEM.
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why we find increased numbers of OT-II T cells in LPS-inflamed 
ear pinnae 24 h after cell transfer.
Motile behavior of the transferred OT-II T  cells in the 
resting ear pinnae was restricted, demonstrating low speeds 
and displacement rate (Figures  3A–C; Videos S1 and S2 in 
Supplementary Material). Surprisingly, in inflamed ears, OT-II 
T  cells demonstrated higher motility and more cells moved 
faster than 2 μm/min, below which cells are considered to have 
arrested their movement (16). OT-II T cells in inflamed tissues 
also had an increased displacement rate compared with the 
OT-II T cells in PBS-injected ears (Figures 3A–D). The displace-
ment rate of the OT-II T cells in LPS-injected ears was similar 
to that of T cells in LNs or peripheral tissues and suggests that 
the cells are not confined in the inflamed tissue (17, 18). The 
OT-II T cells in inflamed ears did not display directional bias 
as indicated by their low meandering indexes (Figure 3E). Such 
highly motile behavior is suggestive of a lack of stable cellular 
interactions. Consistent with this, the OT-II T  cells were not 
seen to form stable contacts with infiltrating DCs (Videos S1 
and S2 in Supplementary Material).
s1P Promotes Persistence of activated 
cD4 T cells at inflamed Tissue sites
The lack of cellular interactions in the inflamed ears suggested 
that soluble mediator(s) may be more likely to be responsible 
for the increased persistence of the OT-II T cells. Many soluble 
mediators that regulate cell migration signal via G-protein cou-
pled receptors. Signaling through these receptors can be blocked 
by treatment with Pertussis Toxin (PTX) (19–21). Before transfer, 
FigUre 3 | Activated CD4 T cells have increased velocity and displacement rate in lipopolysaccharide (LPS)-inflamed sites. Activated OT-II T cells were transferred 
into the ear pinnae of mice injected with PBS or LPS 24 h previously. After a further 24 h, mice were anesthetized, and OT-II T cells imaged by intravital multiphoton 
microscopy. Data show tracks of individual cells from the ear of one mouse per treatment (a) or combined data to show velocity (B), number of cells per mouse 
moving above 2 μm/min (c), displacement rate (D) or meandering index (e). In panels (B,D,e), each symbol represents a cell, and the horizontal line indicates the 
mean of the group, in panel (c) each symbol represents a mouse, and the horizontal line shows the mean of the group; error bars are SEM. Three animals were 
analyzed per treatment.
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we treated activated OT-II T cells with vehicle or PTX and exam-
ined the percentages and numbers of OT-II T  cells in the ear 
and in the downstream draining LN 24  h after transfer. While 
PTX did not alter the numbers of OT-II T cells that remained in 
resting ear pinnae, it greatly reduced the number of OT-II T cells 
in inflamed ears, without significantly increasing the number of 
OT-II T cells found in the draining LN (Figure 4).
Pertussis toxin blocks the activity of chemokine receptors and 
receptors for the sphingolipid, S1P, all of which are associated 
with cell migration (1, 19–21). To differentiate between roles 
for chemokines and S1P, we treated the activated OT-II T cells 
with FTY720, a functional antagonist of S1P receptors (1, 22), 
before transfer. Unexpectedly, FTY720 treatment greatly reduced 
the numbers of OT-II T cells at the inflamed tissue site, suggest-
ing that S1P, rather than chemokines were responsible for the 
increased recovery of OT-II T cells from inflamed as compared 
with resting ear pinnae (Figure 5A). FTY720 treatment did not 
increase the numbers of T cells recovered from the downstream 
draining LN demonstrating that it did not increase T cell migra-
tion out of inflamed ears.
FTY720 causes internalization of S1P receptors, preventing 
cells from sensing S1P gradients in  vivo. It is possible that 
in vitro FTY720 treatment caused some S1P receptor signaling. 
To confirm whether the effect we observed was due to agonist or 
antagonist effects of FTY720, we treated activated OT-II T cells 
with a specific S1PR1 antagonist, W146, or agonist, SEW2871. 
These agents act only on the S1PR1, the S1P receptor associated 
with the regulation of T cell exit from lymphoid organs (23, 24). 
Activated OT-II T  cells pretreated with W146 phenocopied 
those treated with FTY720 with fewer OT-II T cells recovered 
FigUre 4 | Signals through G protein-coupled receptors cause increased persistence of activated CD4 T cells at lipopolysaccharide (LPS)-inflamed sites. Activated 
OT-II T cells were treated with vehicle or pertussis toxin (PTX) before transfer into the ear pinnae of mice injected with PBS or LPS, 24 h earlier. After a further 24 h, 
the percentages and numbers of transferred OT-II T cells in the homogenized ear or draining lymph node were examined by flow cytometry. Data are combined from 
two to three independent experiments with ≥3 animals per group. In this figure, p < 0.01 is indicated by **; p < 0.001 is indicated by ***; and p < 0.0001 by ****; 
n.s., non-significant.
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from inflamed ears compared with ears injected with vehicle 
treated OT-II T cells (Figure 5B). By contrast, pretreatment of 
activated OT-II T cells with the S1P1R agonist, SEW2871, did 
not alter the numbers of OT-II T cells recovered from inflamed 
sites. SEW2871 pretreatment did, however, increase the recov-
ery of OT-II T cells from resting ears to levels similar as from 
inflamed ears. These data demonstrate that signals through the 
S1P1R are sufficient to promote CD4 T  cell persistence 24  h 
posttransfer (Figure  5B). Notably, neither treatment altered 
the numbers of OT-II T cells recovered from the draining LNs 
(Figure 5B).
s1P1r on activated OT-ii T cells Mediates 
cell Movement In Vivo
We were surprised that the OT-II T cells were responsive to S1P 
signals as S1PR1 is reported to be downregulated on recently 
activated T  cells (22). Activated OT-II T  cells before transfer 
expressed high levels of CD69, indicative of their recent exposure 
to antigen in vitro. However, a sizable proportion of the cells were 
also positive for S1PR1; these cells expressed slightly reduced 
levels of CD69 (Figure 6A).
OT-II T cells isolated from the ear pinnae expressed small but 
significantly higher levels of CD69 than those in the LNs, regard-
less of whether the ear had been inflamed or not (Figure 6B). 
However, neither treatment with S1PR1 antagonists nor the 
agonist affected CD69 expression (Figure 6C). These data suggest 
that the increased persistence of CD4 T cells at inflamed sites was 
not mediated via CD69 and that modulation of S1PR1 signaling 
did not affect the expression of CD69.
To investigate how S1P promoted the persistence of activated 
OT-II T  cells, we imaged the behavior of the FTY720-treated 
OT-II T cells in inflamed ears. Activated CD4 T cells pretreated 
with FTY720 and injected into LPS-inflamed ear pinnae had 
reduced cell velocity with fewer cells moving above 2 μm/min 
(Video S3 in Supplementary Material; Figures 7A,B) compared 
with control activated T cells. Their behavior was, therefore, simi-
lar to that seen in non-inflamed ears (Figure 3). FTY720-treated 
cells had similar displacement rates and meandering indices 
compared with control T cells transferred into LPS-inflamed ears 
suggesting either that FTY720 treatment did not fully inhibit 
S1P signal or that additional molecules, such as chemokines and 
adhesion molecules, are involved in regulating T  cell motility 
within inflamed tissues (25, 26). Importantly, we did not observe 
any direct toxicity of FTY720 as the vast majority of FTY720-
treated OT-II T  cells cultured in  vitro were viable 24  h later 
(Figure  7C). Together, these data indicate that S1P may act to 
increase CD4 T cell persistence by promoting CD4 T cell survival 
at the inflamed site.
inflamed Mouse and human Tissues have 
increased levels of the s1P generating 
enzyme, sPhK1
The levels of extracellular S1P available to cells in tissues are 
difficult to measure with any accuracy ex vivo (1). To determine 
FigUre 5 | Signals through S1PR1 cause increased persistence of activated CD4 T cells at lipopolysaccharide (LPS)-inflamed sites. Activated OT-II T cells were 
treated with vehicle or FTY720 (a), or S1P1 receptor specific antagonist (W146) or agonist (SEW2871) (B) before transfer into the ear pinnae of mice injected with 
PBS or LPS 24 h earlier. After a further 24 h, the percentages and numbers of transferred OT-II T cells in the homogenized ear or draining lymph node were 
examined by flow cytometry. Data are combined from two to three independent experiments with ≥3 animals per group. In this figure, p < 0.05 is indicated by *; 
p < 0.01 is indicated by **; p < 0.001 is indicated by ***; and p < 0.0001 by ****; n.s., non-significant.
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whether inflammation may alter the amount of S1P at tissue 
sites, we quantified the levels of SPHK1, an enzyme that drives 
the conversion of sphingosine to S1P and which has been associ-
ated with mucosal inflammation in clinical samples and animal 
models (1, 27, 28). 24 h after injection of LPS, levels of SPHK1 
were increased in inflamed ear pinnae (Figure  8A) suggest-
ing inflammation drives the production of S1P. To investigate 
whether inflamed human tissues also have altered levels of S1P, 
FigUre 6 | CD69 and S1PR1 expression on CD4 T cells before and following cell transfer. Activated OT-II T cells were analyzed before cell transfer (a) for 
expression of CD69 and S1PR1 or for CD69 expression ex vivo 24 h after transfer into resting (PBS) or inflamed [lipopolysaccharide (LPS)] ear pinnae (B,c). Before 
transfer, the OT-II T cells were treated with an S1PR1 antagonist or agonist as in Figure 5B. In panel (a), cells are gated on live CD4+ CD45+ cells; representative 
of three independent samples. In panels (B,c), data are combined from two to three independent experiments with ≥3 animals per group. In this figure, p < 0.05 is 
indicated by * and p < 0.001 by **.
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we analyzed the levels of SPHK1 in biopsies taken from patients 
with the inflammatory autoimmune disease, RA, or from less 
inflammatory OA patients. Importantly, CD4 T cells are known 
to accumulate in RA synovial tissues and contribute to disease 
(29). As in the mouse samples, inflamed RA, but not OA, syno-
vial tissues had raised levels of SPHK1 (Figure 8B).
DiscUssiOn
T  cell migration is a vital process for the immune system in 
homeostasis and following infection (2, 13). It enables T cells to 
navigate from lymphoid organs following activation to inflamed 
peripheral tissues. At inflamed sites, CD4 T cells can coordinate 
the clearance of pathogens but can also contribute to damaging 
chronic inflammation. Here, we have investigated factors that 
affect the persistence of activated CD4 T cells at inflamed sites. 
By taking a reductionist approach, we have focused on mediators 
involved in cell persistence rather than recruitment. An improved 
understanding of such factors has the potential to reveal targets 
to either enhance the persistence of activated CD4 T  cells in 
peripheral tissues, for example in a vaccine setting, or reduce 
them in chronic inflammatory diseases such as RA.
We have found that inflammation increases the number of 
activated CD4 T cells in tissues. This increased persistence was 
not a consequence of increased proliferation and similar numbers 
of CD4 T cells were found in the draining LN and beyond. The 
similar ability to migrate to the draining LN from the resting 
or inflamed tissue suggests that inflammation increases the 
survival of CD4 T  cells in the tissue itself. However, we were 
unable to directly demonstrate improved survival of the trans-
ferred OT-II T  cells in inflamed ears, leaving the mechanism 
of the inflammation-induced increase in CD4 T cells currently 
unclear. Our attempts to identify dying CD4 T  cells may have 
been hindered by the rapid clearance of apoptotic cells by tissue 
macrophages (30). What is clear is that S1P plays a critical role in 
promoting the persistence of activated CD4 T cells at sites of acute 
inflammation.
Sphingosine-1-phosphate is a pleiotropic molecule that has 
numerous effects on cells including proliferation, migration, cell 
adhesion and survival (31). Mendoza et al. (32) have recently reported 
FigUre 7 | Signals through S1P1 receptor cause increased CD4 T cell movement in inflamed tissues. Activated OT-II T cells were treated with vehicle or FTY720 
before transfer into the ear pinnae of mice injected with PBS or lipopolysaccharide (LPS) 24 h earlier. After a further 24 h, mice were anesthetized and OT-II T cells 
imaged by multiphoton microscopy. Data show tracks of individual cells from the ear of one mouse per treatment (a) or velocity, number of cells per mouse moving 
above 2 μm/min, displacement rate and meandering index. For velocity, displacement rate, and meandering index, each symbol represents a cell, and the horizontal 
line indicates the mean of the group. For numbers of cells moving above 2 μm/min, each symbol represents a mouse, and the horizontal line shows the mean of the 
group; error bars are SEM. Data are combined from three animals per group (B). In panel (c), activated OT-II T cells treated with vehicle or FTY720 were rested 
overnight in vitro and viability determine by exclusion of viability dye. Cells are gated on activated cells, and data are representative of three experiments.
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a role for S1PR1 in enhancing the survival of naïve circulating 
CD4 T cells. Our results extend these data by demonstrating a 
key role for S1PR1 in regulating the number of activated CD4 
T  cells found in inflamed sites. Activated CD4 T  cells treated 
with the S1P receptor antagonist, FTY720, move more slowly 
compared with control T cells. The low T cell velocity following 
either treatment with FTY720 (2.2 ±  2.2 μm/min) or transfer 
into non-inflamed ears (1.3 ± 1.6 μm/min) is similar to that of 
T cells at early stages of apoptosis in vivo (33). Together, these 
data indicate that inflammation-induced S1P may promote the 
survival of activated CD4 T cells.
By contrast, our finding that treatment of activated OT-II 
cells T cells with S1PR1 antagonists did not reduce the survival 
of these cells in  vitro, suggest that S1P may not be acting as a 
survival signal in our in vivo model. Alternatively, S1P provides 
protection from an apoptosis signal present in the tissue itself. 
Future experiments will address the fate of the transferred T cells 
and determine whether S1P acts directly or indirectly to increase 
FigUre 8 | Inflammation leads to an increase in sphingosine kinase-1 (SPHK1). Levels of SPHK1 in the ear pinnae of mice injected with PBS or lipopolysaccharide 
(LPS) 24 h (a) previously or in sections prepared from osteoarthritis (OA) or rheumatoid arthritis (RA) patients (B) were examined. Sections were immunostained with 
anti-SHPK1 (brown) and DAPI (blue), scale bar in panel (a) is 20 µm (a). Data are representative or combined from five animals per group or four OA and four RA 
patients. In panel (B), SLL, synovial lining; SUL, synovial sub-lining; and VEL, vascular endothelial lining, and staining graded on a scale of 0–4 (0 = no cells, 
1 = <25%, 2 = <25–50%, 3 = <50–75%, 4 = 75%) by two blinded observers on two independent occasions.
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persistence of CD4 T cells at sites of acute inflammation by pro-
moting cell survival and/or by other mechanisms.
Blocking S1PR1 either via FTY720 or the S1PR1 specific 
antagonist, W146, led to a reduction in the numbers of trans-
ferred OT-II T cells recovered from the ear without affecting the 
numbers of cells in the draining LN. These data conflict, in some 
instances, with previous publications that examined the migra-
tion of total spleen cells or activated CD4 T cells from resting or 
inflamed tissue sites (34, 35). A number of experimental details 
differ between our work and these previous studies. Most notably 
we have examined the injection site and the draining LN rather 
than only assessing cellular migration in the draining LN.
Ledgerwood et al. found the treatment of resting spleen cells 
with FTY720 or SEW2871 led to a reduction in the numbers of 
transferred cells recovered from the draining LN. The authors 
concluded that FTY720 acts as an agonist and that signals through 
S1PR1 inhibit cell migration (34). In our hands, FTY720 acts as 
an antagonist: the persistence of activated CD4 T cells in inflamed 
sites is inhibited following treatment with FTY720, PTX, and 
the S1PR1 specific antagonist, W146. Importantly, treatment of 
activated CD4 T cells with the S1PR1 specific agonist, SEW2871, 
before transfer, was sufficient to increase cell recovery from non-
inflamed ears.
Recent studies suggest that downregulation of S1PR1 accom-
panies the differentiation of Trm cells (5, 6, 36). Our data could be 
interpreted to suggest that S1P signals may promote Trm genera-
tion via increasing survival of activated CD4 T cells in inflamed 
tissues. This is likely an over-simplification of the complex events 
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culminating in Trm cell formation. Most significantly, our data 
are focused on very early time points while Trm differentiation 
is likely to occur in the weeks following a response. Our data 
do suggest, however, that disruption of S1P signaling early after 
T cell activation may counter rather than promote the generation 
of Trm cells.
Our studies have focused on examining the role of S1P in the 
context of Th1 cell persistence in acute and chronically inflamed 
tissues, but likely reflect a broader regulation of T cell activity at 
peripheral sites. The similar expression of S1PR1 on Th1 and Th2 
cells suggests that Th2 cells are likely to be regulated in a similar 
fashion in vivo (37). Expression of S1PR1 is also required for the 
accumulation of regulatory T cells in tumors indicating that these 
cells may also be affected by S1P at inflamed tissues (38).
Currently, FTY720 is an approved treatment for multiple 
sclerosis and can reduce the onset of disease in animal models of 
inflammatory disease such as RA (39–43). In these approaches, 
systemic inhibition of S1P receptors is thought to reduce the 
entry of activated CD4 T cells into target tissues by preventing 
CD4 T  cells from leaving lymphoid organs. Our finding that 
SPHK1 is increased in inflamed synovial tissue from RA patients 
suggests that S1P may also play a role in regulating the accumula-
tion of activated CD4 T cells in human diseases. Indeed, there is a 
growing realization that S1P levels are increased in inflammation. 
S1P and S1P receptors are reported to be increased in synovial 
samples from RA compared with OA patients (44, 45). In addi-
tion, S1P is found at raised levels in the bronchoalveolar lavage 
of asthma patients and in intestinal tissue in preclinical animal 
models and clinical samples from individuals with inflammatory 
bowel disease (28, 46). Chronic inflammation is a multifactorial 
process involving a plethora of different cell types and inflam-
matory molecules (47). Our current in vivo data are limited to 
an acute model of inflammation in mice. Our future studies 
will investigate whether S1P influences the switch from acute to 
chronic disease and the maintenance of inflammation by promot-
ing activated CD4 T cell persistence in these settings.
In summary, we have shown that acute inflammation promotes 
the persistence of CD4 T  cells at tissue sites and that signals 
through S1PR1 are both necessary and sufficient for this main-
tenance. An increased understanding of how S1P mediates this 
effect could reveal opportunities to manipulate the levels of S1P 
in peripheral tissues to promote or reduce survival and persis-
tence of activated CD4 T cells.
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